Antitumor diarylsulfonylureas: Novel agents with unfulfilled promise

Peter J. Houghton, Janet A. Houghton

Research output: Contribution to journalArticlepeer-review

36 Scopus citations


Diarylsulfonylureas represent a class of antitumor agent with significant therapeutic efficacy against rodent and human models of cancer. Despite the exciting preclinical activity of sulofenur, the prototypic agent, clinical activity was poor. Here we review the activity of sulofenur and a second generation diarylsulfonylurea, LY295501 N-[5-(2,3-dihydrobenzofuryl) sulfonyl]-N'-(3,4-dichlorophenyl)urea, against colon tumor xenografts, and some of the cellular pharmacology of this class of antitumor agents.

Original languageEnglish (US)
Pages (from-to)271-280
Number of pages10
JournalInvestigational New Drugs
Issue number3
StatePublished - 1996
Externally publishedYes


  • Diarylsulfonylureas
  • Pharmacology
  • Xenografts

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Antitumor diarylsulfonylureas: Novel agents with unfulfilled promise'. Together they form a unique fingerprint.

Cite this